Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04840342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MR Antagonist and LSD1

StatusCompleted
PhasePhase 4
Started2022-02-03
View on ClinicalTrials.gov ↗

Amendment history

2026-10-02
Trial completed
Study completion confirmed: December 2025 (last estimated June 2026)
2026-04-24
Study Status v6
Primary completion dateestimated 2026-02→confirmed 2025-09-15
2025-11-04
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v5
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2024-08-06
2 amendments v3-v4
2 re-verifications since 2023-07-27, no change to tracked fields
2022-07-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2021-07→confirmed 2022-02-03
2021-05-13
Study Status, Sponsor/Collaborators, Oversight, Outcome Measures, Eligibility v1
Eligibility criteria-16 characters
Inclusion Criteria: untreated as well as currently treated hypertensives; rs587168 allele carriers; not on more than two anti-hypertensives; normal renal, metabolic, electrolyte, and CBC laboratory tests; self-identified Black race; and age >17 yrs. Exclusion Criteria: known cardiac disease other than HTN; renal, circulatory or neurologic diseases; diabetes; smoking; secondary HTN as indicated by history, physical examination or screening blood and urine tests; smoking; any drug therapy, except for anti-hypertensives and stable thyroid medication replacement.
2021-04-07
Original filing
Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).
Trial Details
NCT Number NCT04840342
Lead Sponsor Brigham and Women's Hospital
Conditions Hypertension, Mineralocorticoid Excess
Enrollment 300 participants
Start Date 2022-02-03
Primary Completion 2025-09-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-10-01